French Insurer to Cover Epigenomics' Colorectal Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics announced today that Swiss Life will provide insurance coverage for the firm's Epi proColon 2.0 colorectal cancer test as part of a preventive health program in France.

Swiss Life, France's third-largest private health insurer, is the first French insurer to cover the test, which uses Epigenomics' colorectal cancer biomarker Septin9 in blood plasma, and will reimburse for the test at up to 50 percent of the cost. French Social Security does not cover Epi proColon 2.0, Berlin-based Epigenomics noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.